QuesGen Systems, a provider of research services to organizations and scientists working on brain health and treatments for traumatic brain injury (TBI), is expanding its business and has announced the establishment of a new business relationship with ImmunArray, a private diagnostics company with headquarters in Rehovot, Israel, and…
The bone disorder known as idiopathic osteonecrosis of the femoral head (ONFH) might be caused by high-dose steroid therapy — a common treatment for systemic lupus erythematosus (SLE). A research team at Kyoto University Hospital, Japan, has developed a minimally invasive method to save the thighbone from breaking down,…
In systemic lupus erythematosus (SLE) patients, intestinal dysbiosis is associated with activation of pro-inflammatory cells. As such, rescuing gut microbiota with beneficial bacteria strains improves patients’ inflammatory profile, according to a study entitled “Th17 responses and natural IgM antibodies are related to gut microbiota composition in systemic lupus erythematosus patients”…
Corbus Pharmaceuticals announced the addition of a protocol amendment to one of the company’s existing Investigational New Drug (IND) Applications with the FDA for a Phase 2 clinical trial of Resunab for the treatment of systemic lupus erythematosus (SLE), an important step to initiate a multicenter placebo-controlled SLE trial. The clinical study,…
In a landmark study, principal researcher Virginia Pascual at the Baylor Institute for Immunology Research, and colleagues, investigated the molecular diversity of lupus and found that a personalized immuno-monitoring approach allows for classification of patients into specific disease groups. Researchers believe these results may explain why lupus clinical trials have a low success rate…
British Columbia-based Aurinia Pharmaceuticals has announced positive results from the fourth and final safety review of the company’s Phase 2b AURA LV clinical trial, which is evaluating the efficacy of its lead drug voclosporin as a treatment for active lupus nephritis. The review was conducted by the Data and Safety…
Researchers found that single-nucleotide polymorphisms (SNPs) at a specific genomic location, the FCGR2B-FCRLA locus, is involved in the response of systemic lupus erythematosus (SLE) and lupus nephritis patients to cyclophosphamide treatment. The research, “Response to Intravenous Cyclophosphamide Treatment for Lupus Nephritis Associated with Polymorphisms in the FCGR2B-FCRLA Locus,” was published in The…
Three organizations focused on helping patients with lupus are banding together once again to recognize an outstanding research project. The Alliance for Lupus Research, the Lupus Foundation of America, and the Lupus Research Institute are calling for research nominations to win the Lupus Insight…
The American Autoimmune Related Diseases Association (AARDA) is celebrating its 25th anniversary this month with the inauguration of its yearlong Autoimmune Heroes campaign that names actresses Kellie Martin (@kelliemartin) and Haley Ramm (@halesbells), along with her mother Barbara Ramm (@BarbeeVintage), as the first #AutoimmuneHeroes for their help in raising public awareness and promoting…
Using next-generation DNA sequencing technology, researchers have targeted 16 specific regions of the human genome associated with increased susceptibility to systemic lupus erythematosus (SLE), identifying more than 1,000 DNA variations that regulate the expression of genes associated with immune responses and SLE pathology. The variations are linked to disease susceptibility. The study,…